Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Current Deferred Revenue: 2020-2023

Historic Current Deferred Revenue for Janux Therapeutics (JANX) over the last 4 years, with Dec 2023 value amounting to $1.7 million.

  • Janux Therapeutics' Current Deferred Revenue fell 98.24% to $94,000 in Q2 2024 from the same period last year, while for Jun 2024 it was $94,000, marking a year-over-year decrease of 98.24%. This contributed to the annual value of $1.7 million for FY2023, which is 68.46% down from last year.
  • Latest data reveals that Janux Therapeutics reported Current Deferred Revenue of $1.7 million as of FY2023, which was down 68.46% from $5.4 million recorded in FY2022.
  • Janux Therapeutics' Current Deferred Revenue's 5-year high stood at $8.0 million during FY2020, with a 5-year trough of $1.7 million in FY2023.
  • Its 3-year average for Current Deferred Revenue is $4.1 million, with a median of $5.2 million in 2021.
  • In the last 5 years, Janux Therapeutics' Current Deferred Revenue rose by 4.71% in 2022 and then tumbled by 68.46% in 2023.
  • Over the past 4 years, Janux Therapeutics' Current Deferred Revenue (Yearly) stood at $8.0 million in 2020, then slumped by 35.46% to $5.2 million in 2021, then rose by 4.71% to $5.4 million in 2022, then plummeted by 68.46% to $1.7 million in 2023.